A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

NCT01494233 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

373

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome

Interventions

DRUG: 250 mg LX1033 tablets
DRUG: Placebo tablet

Sponsor

Lexicon Pharmaceuticals